AIM ImmunoTech Inc. (AIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 60K 120K 180K FY24: 170K FY25: 88K FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-21M -14M -7M 0 7M 14M 21M FY24: -19.8M FY25: -11.7M FY24 FY25

Net Income Annual

-18M -12M -6M 0 6M 12M 18M FY24: -17.3M FY25: -14M FY24 FY25

Cost of Revenue Annual

0 50K 100K 150K FY24: 31K FY25: 128K FY24 FY25

Operating Cash Flow Annual

-18M -12M -6M 0 6M 12M 18M FY24: -14.9M FY25: -11M FY24 FY25

Free Cash Flow Annual

-18M -12M -6M 0 6M 12M 18M FY22: -16.2M FY24: -14.9M FY22 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 600K 1.2M 1.8M FY24: 560.2K FY25: 1.6M FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '23: -0.43 Q4 '23: -0.60 Q1 '24: -0.64 Q2 '24: -3.54 Q3 '24: -9.38 Q4 '24: -19.04 Q1 '26: -3.24 Q2 '26: 0.01 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.